Painting a Rosy Picture, Beleaguered Elan Seeks To Leave Its Troubles Behind
This article was originally published in The Pink Sheet Daily
Executive Summary
Elan reveals a hidden sweetener in its J&J deal, which will enable it to bid for the half of Tysabri it doesn't already own in the event Biogen is bought.
You may also be interested in...
Deals Of The Week: Mylan/Agila, UCB/Biotie, Jazz/Concert…
Elan peels off assets to attract suitors: First Biogen buys out Elan’s 50% interest in Tysabri, then Royalty Pharma maneuvers to buy out Elan.
Court Date for Biogen and Elan Set for Sept. 3
The partners, who are litigating over Tysabri, face off earlier than expected.
Court Date for Biogen and Elan Set for Sept. 3
The partners, who are litigating over Tysabri, face off earlier than expected.